Lars is a biotech specialist with 35 years of cutting edge biomedical research, drug discovery, biopharma, biotech-startup, and biotech investment experience. He has been a driving force behind the Crescat Biotech stock selection since the theme’s inception almost four years ago. After earning a PhD in Molecular Biology from Aarhus University and a Medicinal Chemistry degree, Lars made seminal discoveries about regulation of human growth hormone expression while a postdoctoral researcher at UC San Diego Medical School. Lars led a biotherapeutics discovery lab at Amgen for 15 years, validating novel therapeutic targets and leading invention and preclinical development of small molecule drugs, antibodies, and other therapeutic candidates including APRIL, BCMA, Neuritin, Neuregulin, DKK, and OPG (which led to the blockbusters Prolia and Xgeva) for treatment of cancer, osteoporosis, autoimmune and neurodegenerative diseases. He also evaluated countless in-licensing and acquisition opportunities for Amgen BD. Lars co-founded Logix Pharmaceuticals Inc. and Medolution Inc. to continue discovery and development of JAK3, BTK, and EGFR inhibitors, one of which is in phase 2 clinical trials for lung cancer. Lars is an inventor on several US patents and author of 28 research articles published in Science, Nature, Cell, and other leading scientific journals. His papers have received >7,100 citations. For the last five years Lars has focused on in-depth biotech equity research for institutional investors.

< Back to TEAM